Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 19/20 | 0.77 |
| ▸ | JAK2 | O60674 | 11/20 | 0.77 |
| ▸ | JAK1 | P23458 | 11/20 | 0.77 |
| ▸ | TYK2 | P29597 | 6/20 | 0.77 |
| ▸ | PKN2 | Q16513 | 4/20 | 0.77 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.77 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.77 |
| ▸ | STK3 | Q13188 | 3/20 | 0.77 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.77 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.77 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.77 |
| ▸ | MARK3 | P27448 | 2/20 | 0.77 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.77 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.77 |
| ▸ | ABL1 | P00519 | 2/20 | 0.77 |
| ▸ | LCK | P06239 | 2/20 | 0.77 |
| ▸ | FYN | P06241 | 2/20 | 0.77 |
| ▸ | RET | P07949 | 2/20 | 0.77 |
| ▸ | DMPK | Q09013 | 2/20 | 0.77 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tofacitinib SCHEMBL11949309 | 0.87 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 | |
| Tofacitinib SCHEMBL28416782 | 0.87 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 | |
| Tofacitinib SCHEMBL29351183 | 0.87 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 | |
| Tasocitinib SCHEMBL23058868 | 0.87 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 | |
| Tofacitinib SCHEMBL322753 | 0.87 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 | |
| Tofacitinib SCHEMBL23199919 | 0.87 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 | |
| Tofacitinib SCHEMBL30925309 | 0.87 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 | |
| Tofacitinib SCHEMBL29816283 | 0.87 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 | |
| Tasocitinib SCHEMBL30341861 | 0.87 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 | |
| Tofacitinib SCHEMBL1120705 | 0.87 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | JAK3 3/4885JAK2 1/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.